Serum levels of the adrenal androgen dehydroepiandrosterone (DHEA) peak in men and women in the 3rd decade of life and decrease progressively with age. Increasing numbers of middle-aged and older individuals consume over-the-counter preparations of DHEA hoping it will retard aging by increasing muscle and bone mass and strength, decreasing fat, and improving immunologic and neurobehavioral functions. Because DHEA can serve as a precursor to more potent androgens and estrogens, like testosterone (T), dihydrotestosterone (DHT), and 
INTRODUCTION
Dehydroepiandrosterone (DHEA) is produced by the adrenal cortex and is the most abundant steroid in humans. DHEA exerts its actions via androgen receptor (AR) and estrogen receptor (ER)-mediated effects directly or after enzymatic conversion to androgen or estrogen, (34) as well as by sex steroid receptor-independent mechanisms (58) . Serum DHEA levels in aged men and women decrease by 75%-80% from peak levels (44). DHEA is available as a dietary supplement and is increasingly self-prescribed for its alleged anti-aging effects, with reported beneficial effects on body composition and cardiometabolic, immune and neurobehavioral functions (3) . Humans and other primates are unique among animal species in having adrenals that secrete large amounts of the inactive steroid precursors DHEA and its sulfate, DHEA-S (33, 38) .
In aged adults, the use of DHEA as a supplement is of potential concern in that DHEA can be metabolized to androgens or estrogens and may stimulate proliferation of cancer cells within the prostate or breast. In that context, controversy exists as to whether DHEA enhances or reduces the risk of prostate and breast cancer (1) . Although DHEA has been reported to exert potent cancer protective effects in preclinical rodent models of prostate cancer (48, 58) , its effects on human prostate cancer cells remain to be elucidated. Epidemiological data are confusing, in that the age-related decline in DHEA, testosterone and estrogens may protect against increasing occurrence of hormone-sensitive cancers (40) ; yet elevated serum levels of DHEA and DHEAS have been associated with decreased cancer rates (16) .
In this study, the well-characterized, AR-positive human prostate cancer LNCaP cell line was used to compare the effects of DHEA with those of testosterone (T), dihydrotestosterone (DHT), and 17-beta estradiol (E 2 ) on cell proliferation and gene and/or protein expression of AR, PSA, ERβ, IGF-I and IGF-II, IGF type I receptor (IGF-IR), and IGF binding proteins (IGFBPs)-2,3 and -5.
MATERIALS AND METHODS:

CELL CULTURE
LNCaP-FGC cells (androgen-dependent, prostate adenocarcinoma cells derived from lymph node metastasis (CRL1435; American Type Culture Collection, Manassas, VA) were grown in DMEM: F12 (1:1) medium, (Invitrogen, Gaithersburg, MD) with penicillin (100 units/mL), streptomycin (100 µg/mL), L-glutamine (292 µg/mL) (Invitrogen), and 5% Fetal Bovine Serum (FBS, HyClone Laboratories, Inc., Logan, UT) at 37 C in 5% CO 2 and propagated at 1:5 dilutions.
CELL PROLIFERATION ASSAYS
Cell proliferation was estimated using the CellTiter 96 ® Assay (MTT assay) (Promega, 
HORMONE TREATMENTS FOR GENE AND PROTEIN EXPRESSION
LNCaP cells were seeded in triplicate into 6-well tissue culture plates pre-coated with Matrigelmatrix film at a density of 2 x 10 6 cells/well with media and treatments, identical to the proliferation assays. After 2-3 days in the media with 2% CDS, cells were treated for 2 days with a dose range of each hormone from 0 to 10000 nM, and then harvested to extract RNA or protein for the dose response experiments. Time course experiments were set up in a similar manner and cells were treated with 100 nM hormone for multiple time points before being harvested for protein or mRNA analysis and compared with untreated controls at each time point. Three replicates per point were assayed and data from three separate experiments are presented. 
WESTERN BLOT ANALYSIS
RNA EXTRACTION AND REAL TIME QUANTITATIVE -RT-PCR.
RNA was extracted using Trizol reagent (Invitrogen,) according to the manufacturer's manual. The resulting RNA pellet was extracted a second time with Trizol reagent to increase the RNA purity. RNA was quantified spectrophotometrically at 260 nm wavelength. cDNA synthesis and real time RT-PCR were performed as described in Latil et al (35) Further analysis of results using ANCOVA revealed a significant difference in the regression slopes between the control and DHEA, DHT, T, and E 2 (p<0.0001). In addition, comparison of the 95% CIs for the slope of each treatment indicated that cell growth induced by DHEA was significantly lower than that induced by DHT or T, but similar to that induced by E 2 .
RESULTS
EFFECTS OF, DHT, T, DHEA, AND E 2 ON PROSTATE CANCER CELL
PROLIFERATION
Cells were also treated with 0.1 to 10,000 nM of DHT, T, DHEA or E 2 for 5 days to determine comparative dose response between the hormones. Increased dose-dependent cell proliferation occurred with all hormone treatments ( Figure 1B ). Cell growth induced by DHT and T was significantly different from that of control at all concentrations tested, from 0.1nM to 10000nM (p< 0.0001). In contrast, cell growth induced by DHEA or E 2 differed from that of control at concentrations of 10 nM or higher for DHEA (p<0.0001), and 1.0 nM or higher, for E 2 (p<0.016, 1 nM, p<0.001 10-10,000 nM)
EFFECTS OF DHT, T, DHEA AND E 2 ON GENE AND PROTEIN EXPRESSION BY LNCAP CELLS
Androgen Receptor mRNA DHT, T, DHEA and E 2 each decreased AR mRNA levels during a 5-day period (p <0.0001; Fig 2A) , with no significant differences found among the hormone treatments. At 24 h, AR expression was decreased to 48-55 % of control values by DHT, T and E 2 (p< 0.01) , whereas DHEA decreased AR mRNA to 47% of control after 48 h treatment ( p< 0.0003).
In dose response experiments, AR mRNA fold change was reduced to 43% and 52% of control values by DHEA and E 2 , respectively, in a dose dependent manner (all p < 0.01 except E 2 at 100 nM at p= .0366; Figure. 2B ). There was a nonsignificant 30% downward trend of AR mRNA in DHT and T-treated cells. The responses induced by DHEA did not differ significantly from those of the other hormones. However, E 2 demonstrated greater down regulation of AR expression than did DHT at concentrations of 100, 1000, and 10000 nM.
Androgen Receptor Protein
In comparison to the changes seen in the AR mRNA, the AR protein expression did not change significantly in time-or dose-dependent manner in steroid-versus control-treated LNCaP cells (data not shown).
PSA mRNA
DHT and T increased PSA mRNA expression ( Figure 3A ) 2 fold within 6 h (p< 0.01), proceeding in a linear fashion to peak at 6-and 7-fold over control, respectively, at 48 h (p < 0.0001) and 72 h (p < 0.0001). In contrast, there was a 24 h delay in PSA gene induction by DHEA and E 2 . DHEA-induced expression peaked at 5-fold increase versus control (p < 0.0001) and remained unchanged, whereas the E 2 response peaked at 4-fold and decreased at 95 h and 120 h. The patterns of DHEA and E 2 were similar to each other and differed from the patterns of DHT and T. Comparison of least square means revealed that DHT and T had significantly higher fold change in PSA mRNA expression than did DHEA at earlier time points, but by 72 hours, expression was not different among DHEA, DHT, and T. E 2 responsivity did not differ from that of DHEA at 6 and 24 hours, but was significantly lower than that for DHEA at 72 hours and beyond.
In dose response experiments, DHT, T and E 2 stimulated PSA mRNA significantly from 0.1 to 10,000 nM (p<0.0001) ( Figure 3B ), with DHT and T levels peaking at 10 fold increase over control and E 2 peaking at 4.6 fold increase over control. DHEA-induced PSA mRNA expression was significantly increased over control after 1nM and peaked at 5-fold increase.
Comparison of least square mean values revealed significantly greater increments in PSA (nearly 2-fold) at almost all hormone doses of DHT or T versus DHEA or E 2 . The PSA responses to DHEA and E 2 did not differ significantly.
PSA Protein
DHT and T increased PSA protein secretion to a maximum of 342% (DHT) and 325%
(T) of control values at 96 h and 120 h, respectively ( Figure. 3C, p< 0.0001). DHEA and E 2 -stimulated PSA levels were delayed and significantly increased compared with control values after 72 h for DHEA (p< 0.0001) and 48 h for E 2 (p=0.003), with peak values of 222% and 257%, respectively, at 120 h (p< 0.0001). DHEA-stimulated PSA secretion was less than levels induced by DHT and T after 48 h (p< 0.0006). ANCOVA revealed a significant difference in the regression slopes when PSA secretion was regressed against time for all treatments (p< 0.0001).
The 95% CI for β 1 (slope) value for DHEA overlapped with that for E 2 , but not with those for DHT and T.
PSA protein levels increased significantly after DHT, T and E 2 treatments (Figure. dose-related differences in regression slopes for DHEA, DHT, T, and E 2 (p < 0.0001). The 95%
CI for β1 (slope) for DHEA did not overlap those of DHT or T, but did overlap that of E 2 . The peak responses to DHT and T were greater (5 to 6 fold) than those of DHEA or E 2 (3 to 4 fold).
E 2 exerted the weakest effect on IGF-IR induction, with a 2 to 3.5-fold increase between 10 and 10,000 nM. The response of DHEA was similar to those of DHT and T up to 100 nM, and resembled that of E 2 at higher doses. DHT, T, DHEA and E 2 each decreased IGFBP-3 mRNA message levels by a maximum of 30% at 48 hours (p<0.0001, Figure. 6C ). All hormones showed similar patterns of IGFBP-3 suppression, except for E 2 , which lost its inhibitory effect after 72 hours.
IGF-IR Protein
All four hormones reduced IGFBP-3 expression with increasing doses (Figure. 6D ). The inhibitory effects of DHT and T were greater than that of DHEA at 0.1 and 1 nM (p < 0.0001) but at 10nM or higher, there was no significant differences found among the four hormones. 
DISCUSSION
In the United States, DHEA is widely used as an over-the-counter dietary supplement based on its purported, yet controversial, anti-aging benefits to improve body composition, endocrine-metabolic balance, immune, and psychological function, and quality of life (3, 54) .
Because DHEA is a precursor for more potent androgens and estrogens, there is some concern that DHEA supplementation may promote prostate cancer growth or deleterious functions in men with preexisting prostate cancer (1).
This study aimed to evaluate the effects of DHEA on human prostate cancer cells. Well- To our knowledge, this is the first report of reduction of the ERβ mRNA levels in LNCaP cells by these sex steroid hormones. Given that ERβ may play an inhibitory role in the prostate (57) these findings suggest another mechanism whereby sex hormones increase proliferation of prostate cells by decreasing the "brakes" to cell proliferation.
DHEA increased PSA mRNA and protein expression in a pattern similar to that induced by E 2 , but different from those stimulated by DHT-and T. PSA mRNA expression was delayed by 24 hours in DHEA-treated cultures and reached levels 75% that induced by T in the time response experiments, and 50% those of DHT and T in the dose response studies. Prior studies reported a 10-fold increase in PSA expression after 6 days of exposure to 100 nM DHEA and 18-fold increase with T and E 2 treatment (60). In the current experiments, 5-days of treatment revealed a repeated distinction between the greater DHT-and T-induced PSA protein expression (320% and 325%) and the lesser DHEA and E 2 -induced PSA release (222% and 257%, respectively). Importantly, the steroid-induced PSA expression, as determined by ELISA, was standardized by comparing PSA concentrations with total cell numbers to adjust for the effects of the hormones on cell proliferation.
Steroid-induced responses in gene expression of members of the IGF axis were compared among DHEA, DHT, T, and E 2 treatments. The prostatic IGF axis includes IGF-I and IGF-II, the IGF Type I receptor, and IGFBP's 2-5, which have been well characterized in normal and diseased prostate (14, 45) . Increased circulating levels of IGF-I (27, 37), IGFBP-2 (15), and IGF-IR (2) have been associated with increased risk of prostate cancer in men. IGFBP-3 not only associates with and sequesters IGF-I, but also has its own receptor which, when bound, triggers apoptosis (47). PSA is an IGFBP-3 protease (13). As such, PSA can cleave IGFBP-3, releasing the bound IGF-I (increasing proliferation) and preventing IGFBP-3 from attaching to its receptor (inhibiting apoptosis). The net effect might be to increase proliferative potential in the prostate(13).
To our knowledge, this study represents the first demonstration that DHEA, DHT, T, and DHEA circulates in the plasma in a sulfated form, DHEA-S. The DHEA-S levels are 100 to 500 times higher than those of T and 1,000 -10,000 times higher than those of E 2 . Both DHEAS and its sulfatase are present at high levels in the prostate (31) . Non hyperplastic prostate tissue specimens exhibit concentrations of 300 nM DHEA-S and 90 nM DHEA (5). These tissues maintain the capacity to metabolize adrenal androgens to DHT (33) , accounting for up to one sixth of total prostatic DHT (22) . Additionally, steroid metabolizing enzymes and steroid precursors are present in primary prostatic tumors and lymph node metastases (31) . LNCaP cells possess the major enzymes involved in androgen metabolism including the hydroxysteroid dehydrogenases (HSD), 3α HSD, 3β HSD- (23), and 17β HSD4 (10) involved in conversion of DHEA to androstenedione, and T, as well as 5α-reductase for conversion of T to DHT, (21 , 32) . Aromatase activity of LNCaP cells may also contribute to the production of E 2 from DHEA via T or androstenedione. However, the existence of aromatase activity in LNCaP is controversial, having been reported to be absent, (41), weak, (9) or present and modulatable (19) .
Thirdly, DHEA may act more like an estrogen than an androgen in LNCaP cells.
Estrogen-induced growth of LNCaP via the ER has been reported (11) . Also, DHEA, Androstenediol, and T stimulate proliferation of breast cancer cells (36) via ERα, but this is unlikely to be the mechanism in LNCaP cells as they appear to possess ERβ and lack ERα (28).
DHEA may exert its effects in LNCaP cells via binding directly to the ER. DHEA exhibits a low-affinity binding to the ER (as do other androgens, except at very high concentrations.) (46) . DHEA has been found to directly stimulate the estrogen response element (ERE) (8) an effect that could be blocked with an ER antagonist suggesting that DHEA was not metabolized to E 2 but directly interacted with ER. However, this is unlikely to be the explanation because DHEA at 100nM was unable to stimulate ERE previously, whereas DHEA significantly induced cell proliferation at 10nM in the current studies.
If DHEA were to mimic the effects of estrogen in the prostate, then DHEA would present the same paradoxical inhibitory and proliferative influence on the prostate, as do estrogens.
Excessive estrogen induces squamous metaplasia and can act synergistically with androgens to induce glandular hyperplasia. (30). Estrogens have been long used in prostate cancer therapy, and their effects on the prostate, as mediated through the ERα and ERβ, have been reviewed (12, 52) . Estrogens can inhibit prostate cancer xenograft growth in female intact and ovariectomized mice, in the absence of androgens (17) . These inhibitory effects were postulated to occur by direct actions via the ER or by E 2 effects on other cells secreting secondary factors, which influence cancer cell growth. Additionally, ERβ knock-out mice exhibit increased epithelial proliferation compared with that observed in wild-type mice (57) suggesting that ERβ may inhibit prostate growth.
Finally, a recent study defines another important metabolite of DHEA resulting from 7α
hydroxylation of DHEA to 7α-hydroxy-DHEA (7HD) by CYP7B, an epithelial-specific P450 enzyme (39) . The authors identified both CYP7B and the ERβ in human prostate samples, and postulated that CYP7B metabolizes prostatic DHEA to 7HD, which directly activates ER β. This pathway may be important in regulating the balance of androgens and estrogens in the prostate.
Of additional note was the finding that coculture with stromal cells increases epithelial CYP7B 
